Dan brings more than 30 years of leadership experience in biotechnology and oncology, with a proven track-record of creating value around differentiated, IP-rich platforms. Most recently, he served as CEO of Ambrx Biopharma, where his leadership drove a significant increase in company valuation culminating in its successful acquisition.

Earlier in his career, Dan was instrumental at ImClone Systems, contributing to the clinical development, launch, and commercialization of a major oncology therapy while navigating complex intellectual property and inventorship challenges. He also served as CEO of Advaxis, a NASDAQ listed immune-oncology company, where he transformed the organization into a late-stage clinical enterprise, secured substantial growth capital, and forged strategic collaborations with leading pharmaceutical partners.

Dan holds a Juris Doctor (JD) from the Penn State Dickinson Law of The Pennsylvania State University and has served as an officer in the U.S. Marine Corps.